Amundi Funds - European Equity Value R3 GBP CRegister to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | 17.5 | -0.3 | 14.3 | 5.4 | |
+/-Cat | - | 2.4 | 2.4 | 1.9 | -1.4 | |
+/-B’mrk | - | - | - | 1.1 | -2.7 | |
Category: Europe Large-Cap Value Equity | ||||||
Category Benchmark: Morningstar DM Europe Val T... |
Key Stats | ||
NAV 26/09/2024 | GBP 13.74 | |
Day Change | 1.25% | |
Morningstar Category™ | Europe Large-Cap Value Equity | |
IA (formerly IMA) Sector | - | |
ISIN | LU2259108475 | |
Fund Size (Mil) 26/09/2024 | EUR 2440.13 | |
Share Class Size (Mil) 26/09/2024 | GBP 0.31 | |
Max Initial Charge | - | |
Ongoing Charge 23/09/2024 | 0.88% |
Investment Objective: Amundi Funds - European Equity Value R3 GBP C |
The Sub-Fund seeks to increase the value of your investment over the recommended holding period. The Sub-Fund is a financial product that promotes ESG characteristics pursuant to Article 8 of the Disclosure Regulation. The Sub-Fund invests mainly in a broad range of equities of companies that are based in, or do most of their business in Europe. While complying with the above policies, the Sub-Fund may also invest in other equities, money market instruments, deposits and up to 10% of its assets in other UCITS/UCIs. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Andreas Wosol 06/05/2008 | ||
Roberto Campani 06/05/2015 | ||
Inception Date 07/12/2020 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe Value NR EUR | Morningstar DM Europe Val TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Amundi Funds - European Equity Value R3 GBP C | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Novartis AG Registered Shares | Healthcare | 2.59 |
Roche Holding AG | Healthcare | 2.54 |
Neste OYJ | Energy | 2.53 |
Allianz SE | Financial Services | 2.49 |
Sanofi SA | Healthcare | 2.49 |
Increase Decrease New since last portfolio | ||
Amundi Funds - European Equity Value R3 GBP C |